Amgen 2015 Annual Report Download - page 46

Download and view the complete annual report

Please find page 46 of the 2015 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

38
Item 6. SELECTED FINANCIAL DATA
Years ended December 31,
Consolidated Statement of Income Data: 2015 2014 2013 2012 2011
(In millions, except per share data)
Revenues:
Product sales $ 20,944 $ 19,327 $ 18,192 $ 16,639 $ 15,295
Other revenues 718 736 484 626 287
Total revenues 21,662 20,063 18,676 17,265 15,582
Operating expenses:
Cost of sales 4,227 4,422 3,346 3,199 2,708
Research and development 4,070 4,297 4,083 3,380 3,167
Selling, general and administrative 4,846 4,699 5,184 4,814 4,499
Other(1) 49 454 196 295 896
Net income 6,939 5,158 5,081 4,345 3,683
Diluted earnings per share 9.06 6.70 6.64 5.52 4.04
Dividends paid per share 3.16 2.44 1.88 1.44 0.56
As of December 31,
Consolidated Balance Sheet Data: 2015 2014 2013 2012 2011
(In millions)
Total assets $ 71,576 $ 69,009 $ 66,125 $ 54,298 $ 48,871
Total debt(2) 31,556 30,715 32,128 26,529 21,428
Total stockholders’ equity(3) 28,083 25,778 22,096 19,060 19,029
In addition to the following notes, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results
of Operations and the Consolidated Financial Statements and accompanying notes and previously filed Annual Reports on Form
10-K for further information regarding our consolidated results of operations and financial position for periods reported therein
and for known factors that will impact comparability of future results. Also, see Part IV—Note 15, Stockholders’ equity, to the
Consolidated Financial Statements, for information regarding cash dividends declared per share of common stock.
(1) In 2011, we recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in
principle to settle allegations related to our sales and marketing practices.
(2) See Part IV—Note 14, Financing arrangements, to the Consolidated Financial Statements for discussion of our financing
arrangements. In addition, in 2012 and 2011, we issued $5.0 billion and $10.5 billion, respectively, aggregate principal
amount of notes. In 2012, we repaid $123 million of Other notes. In 2011, we repaid our 0.125% Convertible Notes of $2.5
billion.
(3) Throughout the five years ended December 31, 2015, we had a stock repurchase program authorized by the Board of Directors
through which we repurchased $1.9 billion, $0.2 billion, $0.8 billion, $4.7 billion and $8.3 billion, respectively, of Amgen
common stock.